Rosen v. Communication Services Group, Inc.Rosen v. Communication Services Group, Inc.
MEMORANDUM
In this securities fraud action, defendant Communication Services Group, Inc., formerly known as Universal Teleservices Network Corporation, and defendant Douglas R. Colkitt, M.D., move to dismiss the second amended complaint for failure to plead fraud with specificity,
I. Background
The facts alleged in the complaint are as follows.
2
On September 11,1997, plaintiffs Michael J. Rosen and Stephen F. Schatz sold their common stock in The Develop
In addition to cash, UTP issued to each plaintiff a secured convertible debenture, dated September 11,1997, as consideration for the sale of TDC. 4 The debentures were convertible into common stock of UTN upon the occurrence of a “liquidity event,” which included a public offering by UTN. Id. ¶¶ 14, 16; ex. A. Plaintiffs had received other offers, but the prospect of the public offering — and its impact on the value of the debentures — made UTP’s offer unusually attractive. Id. ¶¶ 18-21. On September 22, 1997, UTP obtained a letter of credit and the transaction was closed. Id. ¶ 15.
Prior to the sale, plaintiffs “inquired about the financial and general well being of UTN, UTP and their controlling shareholder, Dr. Colkitt,” and “learned of nothing that would inhibit UTN from going public.” Id. ¶ 22. To the contrary, in the summer of 1997, Randy Warren, acting as Colkitt’s agent and as President of UTP, represented to plaintiffs that Colkitt’s management skills and financial expertise were the foundation of the successful operations of his companies. Id. ¶¶ 17, 22; ex. A. On July 10, 1997, Warren and Colkitt’s accountant gave Colkitt’s personal financial statements to plaintiffs’ business broker. 5 Id. ¶¶23, 28-31. The statements revealed that another company he controlled, Equimed, comprised as much as 30 percent of his assets. Id. ¶ 23.
Also, over the course of four or five conversations, Warren and Jones, another agent of Colkitt, told plaintiffs that UTN would make an initial public offering of its common stock “probably within a year.” Id. ¶¶ 24-26. On September 18, 1997, Warren and Jones accompanied plaintiffs to Florida for a presentation by the brokerage firm Smith Barney and H.J. Meyers & Co., an investment banking company, regarding plans for UTN’s public offering. At the four-day meeting, attended by 23 individuals representing 14 companies, including Equimed, 6 plaintiffs received “written materials concerning UTN going public.” Id. ¶ 26. However, the public offering did not occur.
At some point after the sale was completed, plaintiffs discovered that, prior to the transaction: (1) Colkitt and companies he controlled were under investigation by the United States government for violation of the False Claims Act; and (2) deficiencies existed in Equimed’s accounting practices that led to a dispute with its auditor, Ernst & Young.
Id.
¶¶ 32-33. According to plaintiffs’ allegations, had defendants timely disclosed this
information
— ie., the impediments to UTN’s public offering—
Count one of the complaint alleges violations of § 10(b) of the Securities Exchange Act of 1934, 15 U.S.C, § 78j(b) and
Defendants’ objections to the complaint, in summary, are as follows: (1) fraud was not pleaded with specificity, as required by
II. Discussion
A. Dismissal: failure to plead with specificity
Securities fraud claims must comply with heightened pleading standards set forth in
Our Court of Appeals has cautioned that
Under the Reform Act, the complaint must set forth “each statement alleged to have been misleading, the reason or reasons why the statement is misleading, and, if an allegation regarding the statement or omission is made on information and belief, the complaint shall state with particularity all facts on which that belief is formed.”
9
Although UTN, through its agents, and Dr. Colkitt himself through his agents knew of facts material and critical to Plaintiffs making a proper determination of the value of the Secured Convertible Debenture, UTN and Dr. Colkitt failed to disclose the following facts:
(a) the true financial condition of UTN and Dr. Colkitt;
(b) the devastating effect Dr. Colkitt’s financial and legal troubles with Equimed would have on the ability of UTN to go public, including without limitation:
(1) that Equimed had no procedures in place to assure all adjustments to Equimed’s accounting records, including general journal entries, are reviewed, approved and supported with documentation or appropriate explanations;
(2) that no procedures were in place to assure that routine reconciliations reviews and analysis of its significant account balances were performed on a timely basis;
(3) that Equimed had a dispute with the accounting firm of Ernst & Young, LLP concerning financial statements and the fees charged by that accounting firm; and
(4) that Equimed, Dr. Colkitt and other entities affiliated and/or controlled by Dr. Colkitt were being investigated and sued by the United States for fraud.
^ ^ ^ ^ ^ ^
Upon information and belief, prior to closing the Sale, both UTN and Dr. Colkitt knew of the proceedings brought by the United States against Dr. Colkitt, Equimed and other companies affiliated with Dr. Colkitt as evidenced by the case being filed in the United States District Court for the District of Maryland on August 2,1995.
Dr. Colkitt as controlling shareholder of Equimed, knew or was reckless with regard to his knowledge of the dispute with Ernst & Young regarding accounting issues....
Am. cmplt. ¶¶ 33, 40-41.
While there are some factual allegations of fraud, the complaint falls short of the particularity requirements of
The complaint also violates the clear mandate of the Reform Act to specify “each statement alleged to have been misleading.”
Leave to amend may be denied because of undue delay, bad faith, dilatory motive, prejudice, and futility.
Burlington,
B. Dismissal: failure to state a claim
Defendants also urge dismissal of the federal and state securities, fraud, and misrepresentation claims because: (1) the representations were no more than non-actionable promises of a future occurrence and were not misrepresentations of past or present material fact; and (2) loss causation has not been alleged.
14
More
According to defendants, the failure of UTN to make an initial public offering “is merely an unfulfilled possibility,” and “a promise as to a future occurrence is not, as a matter of law, an act of fraud.” Defs. mem. at 15, 27. Defendants rely on the Restatement Second of Torts:
If the statement is honestly made and the intention in fact exists, one who acts in justifiable reliance upon it cannot maintain an action for deceit if the maker for any reason changes his mind and fails or refuses to carry his expressed intention into effect. If the recipient wishes to have legal assurance that the intention honestly entertained will be carried out, he must see that it is expressed in the form of an enforceable contract, and his action must be on the contract.
Restatement (Second) of Torts ¶ 530(1) cmt. b. Nevertheless, a determination of whether statements were “honestly made [with] the intention in fact” to perform in the future entails questions of fact.
See Fox’s Foods, Inc. v. Kmart Corp.,
Defendants also maintain that plaintiffs “stood to gain upon the contingency of UTN possibly going public within a year, but suffered no risk whatsoever ... [and received] full consideration of $3.5 million.” Def. mem. at 26. Therefore, defendants argue, the alleged mis
The causation issue becomes most critical at the proof stage. Whether the plaintiff has proven causation is usually reserved for the trier of fact. [Plaintiff] MedSystems’ complaint was dismissed at the pleading stage. Although, as noted above, the allegation that it “sustained substantial financial losses as a direct result of the aforementioned misrepresentations and omissions on the part of [defendant] EehoCath” could have more specifically connected the misrepresentation to the alleged loss, ie., investment in a company with little prospects, when we draw all reasonable inferences in plaintiffs favor, we conclude that Med Systems has adequately alleged loss causation.
Id. at 884-85. Although plaintiffs here do not assert that their investment was entirely worthless, the complaint alleges that as a direct result of the misrepresentations, losses were sustained because of the fraudulent overvaluation of the consideration received for their TDC stock. This is a sufficient pleading of loss causation.
“[A] cause of action under a theory of promissory estoppel will lie when a party relies to his or her detriment on the intentional or negligent representations of another party, so that in order to prevent the relying party from being harmed, the inducing party is estopped from showing that the facts are not as the relying party understood them to be.”
Thomas v. E.B. Jermyn Lodge No. 2,
The statute of limitations for a cause of action under § 10(b) of the Securities Act and Rule 10b-5 is one year from the time a plaintiff discovers, or should have discovered, the facts constituting the violation and three years after the violation, whether discovered or not.
See Lampf, Pleva, Lipkind & Petigrow v. Gilbertson,
As one decision in our district has recently stated:
The one-year period begins when plaintiffs had ‘sufficient information of possible wrongdoing to place them on inquiry notice’ or to excite ‘storm warnings’ of culpable activity.’ This happens when ‘a person of ordinary intelligence would have suspected that he or she was being defrauded.’
In re Equimed, Inc.,
No. 98-CV-5374,
This memorandum follows an order dated May 1,2001.
Notes
. Under
. On October 20, 2000, separate lawsuits brought by each plaintiff were consolidated. On November 20, 2000, plaintiffs filed an ' amended complaint. On January 17, 2001, defendants moved to dismiss, and on February 2, 2001, plaintiffs filed a second amended complaint as of course.
. "UTP is not a party to this action because pursuant to an agreement to arbitrate, the within pled causes as action as they may lie against UTP are pending in the American Arbitration Association.” Am. cmplt. ¶ 10.
. Plaintiffs received $1.4 million, and each secured convertible debenture was in the amount of $1,050,000, at 6.11 percent interest. Am. cmplt. ¶ 14. Colkitt did not sign the debenture agreements. Id. ex. A.
. Colkitt's "Personal Financial Statement as of June 20, 1997” is attached to the complaint, am. cmplt. ex. B.
. The complaint includes a list of those present, am. cmplt. at 8; ex. C.
. Section 10(b) of the Securities Exchange Act provides that it is unlawful for any person to "use or employ, in connection with the purchase or sale of any security . .., any manipulative or deceptive device or contrivance in contravention of such rules and regulations as the Commission may prescribe. ...”
. Three purposes for the particularity requirement of
The Reform Act is "primarily directed at the abuse and misuse of securities class action lawsuits where defendant companies choose to settle rather than face the enormous expense of discovery and trial.”
EchoCath,
. The Reform Act:
(1) Misleading statements and omissions In any private action arising under this chapter in which the plaintiff alleges that the defendant—
(A) made an untrue statement of material fact; or
(B) omitted to state a material fact necessary in order to make the statements made, in the light of the circumstances in which they were made, not misleading;
the complaint shall specify each statement alleged to have been misleading, the reason or reasons why the statement is misleading, and, if an allegation regarding the statement or omission is made on information and belief, the complaint shall state with particularity all facts on which that belief is formed.
(2) Required state of mind
In any private action arising under this chapter in which the plaintiff may recover money damages only on proof that the defendant acted with a particular state of mind, the complaint shall, with respect to each act or omission alleged to violate this chapter, state with particularity facts giving rise to a strong inference that the defendant acted with the required state of mind.
. Our Court of Appeals recently recognized the difficulty in applying the mandates of the Reform Act to a situation similar to that presented here. In EP MedSystems, Inc. v. Echo-Cath, the decision explained:
At the outset, it is important to recognize that there are important distinctions between this case and the usual securities actions for which these principals were developed .... [Plaintiff] MedSystems does not base its claim on public misrepresentations or omissions that affected the price of the stock it purchased. Instead, it contends that it was induced to make the substantial $1.4 million investment as a result of personal representations directly made to its executives by [defendant] EchoCath’s executives and that those representations were false and misleading.
In one sense, this action is more akin to a contract action than a securities action, and that may be the claim encompassed in its state law fraud count the District Court did not consider. However, as MedSystems chose to base its initial claim on the securities law, we cannot fault the District Court for analyzing it as such. Nevertheless, the distinction between the fact pattern alleged here and that in the typical securities cases explains why it is difficult to apply the precedent from those cases to may of the issues. It is like the proverbial difficulty of fitting a square peg in a round hole. While the question whether EchoCath’s alleged misrepresentations are immaterial as a matter of law can be readily considered under the precedent, it is far more difficult to do so with the subsequent issues, such as whether MedSystems pled scienter with sufficient particularity, failed to plead reasonable reliance, and failed to plead loss causation.
. Not having set forth the content of the representations or by or to whom they were made during the Florida presentation in September, 1997, the complaint does not meet the particularity requirements of
. Our Court of Appeals has held that the requirements of
. No facts are stated about the action alleged to have been brought by the United States against Equimed or about the dispute with Ernst & Young. Importantly, no attempt has been made to delineate "the nature and scope of plaintiffs' effort to obtain, before filing the complaint, the information needed to plead with particularity” or demonstrated that they have "thoroughly investigate^] all possible sources of information, including but not limited to all publicly available relevant information, before filing [the] complaint.”
Shapiro,
As to scienter, while the complaint, arguably, does not set "forth facts that constitute circumstantial evidence of either reckless or conscious behavior,” it does offer some facts tending to establish "motive or opportunity to commit fraud.”
Advanta,
. A valid securities fraud claim under § 10(b) and Rule 10b-5 requires: (1) that defendants made misstatements or omissions of material fact; (2) with scienter; (3) in connection with a purchase or sale of securities; (4) upon which plaintiffs relied; and (5) plaintiffs’ reliance was the cause of their injury.
EchoCath,
The elements of the tort of negligent misrepresentation are: (1) a misrepresentation of a material fact; (2) the representor must either know of the misrepresentation, must make the misrepresentation without knowledge as to its truth or falsity or must make the presentation under circumstances in which he ought to have known of its falsity; (3) the representor must intend the representation to induce another to act on it; and (4) injury must result to the party acting in justifiable reliance on the misrepresentation.
Gibbs v. Ernst,
Here, the materiality of the alleged omissions (the financial and legal troubles of Colk-itt and Equimed) is
indisputable
— i.e., the information “would have been viewed by the reasonable investor as having significantly altered the 'total mix’ of information made available’ ” to influence plaintiffs' decision to sell their stock UTP.
See EchoCath,
. Defendants also assert that the financial statements are not material because: (1) the suit brought by the government against Colk-itt under the False Claims Act was a qui tam action, filed under seal on August, 2, 1995, and defendants were not aware of the action until August 24, 1998; and (2) litigation was commenced by Equimed against Ernst & Young in August, 1998, subsequent to the sale of UTP stock to plaintiffs. Defs. mem. at 19-20. Because of the pleading deficiencies relating to the financial statements, see note 11, supra, this argument need not be considered at this point.
. According to defendants, plaintiffs cannot succeed in an action for common law fraud or misrepresentation because the underlying transaction was governed by an integrated writing negotiated by sophisticated parties. Defendants rely on
Sunquest Information Sys., Inc.
v.
Dean Witter Reynolds, Inc.,
The Stock Purchase Agreement:
This Agreement, together with the Exhibits and Schedules referred to herein and the Non-Disclosure Agreement dated January 24, 1997, constitutes the entire agreement among the parties, and supersedes any pri- or understandings', agreements or representation by or among the Parties, written or oral, to the extent they are related to the subject matter hereof.
Pltf. mem. ex. 1;
see Burlington,